Early results from a clinical trial presented at the American Association for Cancer Research annual meeting in San Diego have sparked cautious optimism about the potential of CAR-T cell therapy to prevent progression to active multiple myeloma in high-risk patients. The study, which evaluated the investigational therapy Carvykti (ciltacabtagene autoleucel) in individuals with high-risk smoldering multiple myeloma, showed that all 20 participants achieved a stringent complete response, meaning no detectable cancer cells remained in their bodies using the most sensitive tests available.
This outcome represents a significant departure from the typical trajectory of smoldering multiple myeloma, a precursor condition where abnormal plasma cells are present in the bone marrow but symptoms and organ damage associated with active cancer are absent. While some patients remain stable for years, many eventually progress to symptomatic multiple myeloma, particularly those classified as high-risk based on genetic markers and biomarker levels. Current standard approaches for high-risk smoldering myeloma often involve monitoring or early intervention with therapies like Darzalex (daratumumab), which can delay progression but rarely achieve the deep molecular remission seen in this trial.
The findings were shared during a press briefing and scientific session at the AACR meeting held from April 16 to 19, 2023, at the San Diego Convention Center. Researchers from Janssen Pharmaceuticals, the developer of Carvykti, presented updated data from the phase 2 CARTITUDE-4 study, which is evaluating the therapy’s use earlier in the disease course than its current approval for relapsed or refractory multiple myeloma. Carvykti received FDA approval in February 2022 for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
“Seeing 100% of patients achieve a stringent complete response in this high-risk population is unprecedented in the myeloma prevention space,” said Dr. Ecaterina Dumbrava, a myeloma researcher at the University of Texas MD Anderson Cancer Center who was not involved in the trial. “It raises the provocative question of whether we are not just delaying progression but potentially intercepting the disease before it becomes clinically significant. That shifts the conversation toward concepts we’ve historically avoided in myeloma — like the possibility of a functional cure.”
Smoldering multiple myeloma affects an estimated 10% to 15% of individuals with monoclonal gammopathy of undetermined significance (MGUS), a benign condition characterized by low levels of abnormal protein in the blood. While MGUS rarely progresses, smoldering myeloma carries a higher risk of transformation to active cancer, particularly when high-risk features such as specific chromosomal abnormalities (like t(4;14) or del(17p)) or elevated biomarkers are present. Without intervention, median time to progression for high-risk smoldering myeloma can be as short as two years, according to data from the International Myeloma Working Group.
CAR-T therapy works by extracting a patient’s T cells, genetically engineering them to recognize and attack B-cell maturation antigen (BCMA), a protein found on plasma cells, and then reinfusing them to target malignant cells. Carvykti specifically uses a dual-targeting approach toward BCMA, which researchers believe may contribute to its potent activity. Side effects observed in the trial included cytokine release syndrome and neurological events, consistent with known risks of CAR-T therapies, though most were manageable with standard supportive care.
The trial’s design focused on patients with high-risk smoldering myeloma defined by the 20/2/20 criteria: bone marrow plasma cells ≥20%, involved/uninvolved serum free light chain ratio ≥20, and serum monoclonal protein ≥2 g/dL. These criteria identify individuals with a very high likelihood of progressing to active myeloma within two years. Achieving minimal residual disease negativity at this stage suggests the therapy may be eliminating the malignant clone before it can cause clinical harm.
Experts caution that longer follow-up is essential to determine whether these deep responses translate into lasting prevention of progression. As of the latest update, median follow-up in the trial was approximately 14 months, with no patients having progressed to active myeloma or died. Ongoing monitoring will assess durability of response, potential late toxicities, and whether treatment can be discontinued after a fixed period — a concept known as treatment-free remission.
If confirmed in larger, randomized studies, such findings could redefine the treatment paradigm for high-risk smoldering myeloma, shifting from watchful waiting or continuous therapy toward finite, potentially curative immunotherapy. Although, CAR-T therapy remains complex and costly, requiring specialized manufacturing centers and inpatient monitoring for adverse events, which limits its accessibility compared to subcutaneous or intravenous antibody treatments.
The research builds on growing interest in immune interception — the idea of using immunotherapy to eliminate premalignant cells before they evolve into invasive cancer. Similar strategies are being explored in other precursor conditions, such as monoclonal gammopathy of renal significance and certain pre-leukemic states. Success in myeloma could provide a proof-of-concept for applying early interception more broadly in oncology.
Further results from the CARTITUDE-4 trial are expected later in 2023, with additional analyses focusing on quality of life, immunogenicity, and correlative science to understand why some patients might eventually lose response. The study remains active and is recruiting at select academic medical centers in the United States and Europe.
For patients and caregivers navigating decisions about smoldering myeloma, organizations like the International Myeloma Foundation and the Multiple Myeloma Research Foundation offer updated guidance on risk stratification, clinical trial eligibility, and emerging therapies. Healthcare providers continue to emphasize individualized assessment based on genetic profiling, biomarker trends, and patient preferences when considering early intervention.
As research advances, the possibility of preventing multiple myeloma before it causes symptoms moves closer to reality — not as a guarantee, but as a scientifically plausible goal grounded in early evidence of deep, sustained remissions.
Stay informed about developments in myeloma prevention and immunotherapy by following updates from trusted sources such as the American Society of Clinical Oncology, the National Cancer Institute, and peer-reviewed journals like The Lancet Oncology and Journal of Clinical Oncology.
We welcome your thoughts and questions in the comments below. If you found this article informative, please consider sharing it with others who may benefit from understanding the latest progress in blood cancer research.